Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Eye disorder bispecific antibody therapy - China Medical System

Next Previous
Drug Profile

Eye disorder bispecific antibody therapy - China Medical System

Alternative Names: Tetravalent bispecific anti-VEGFA/ANG2 antibody - China Medical System; Tetravalent Bispecific Antibody - China Medical System

Latest Information Update: 04 May 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator YZY Biopharma
  • Class Bispecific antibodies; Eye disorder therapies
  • Mechanism of Action Angiopoietin-2 inhibitors; Vascular endothelial growth factors inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Eye disorders

Most Recent Events

  • 27 Apr 2023 National Medical Products Administration granted approval for clinical trials in neovascular age-related macular degeneration
  • 01 Aug 2022 Preclinical trials in Eye disorders in China before August 2022 (Intravitreous)
  • 26 Jul 2022 China Medical System enters into an asset purchase agreement with YZY Biopharma to acquire all the assets related to VEGF/ANG2 tetravalent bispecific antibody

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top